Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of 9MW3011 in Healthy Volunteers
NCT06389942Phase 1Completed
- Sponsor
- Mabwell
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9MW3011 in polycythemia vera (PV) and beta thalassemia (6 arms), sponsored by Mabwell. Primary endpoint: Adverse Event (including serious adverse event) at Day 99. Started Mar 2023; status: completed.
02
Drugs
9MW3011
03
Conditions
polycythemia vera (PV)beta thalassemia
Beyond the preview
Go deeper on NCT06389942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389942.